Review

Engineering antiphagocytic biomimetic drug carriers

Alicia Sawdon

Department of Chemical Engineering, Michigan Technological University, Houghton, MI 49931, USA

Search for more papers by this author

Ching-An Peng

* Author for correspondence

Department of Chemical Engineering, Michigan Technological University, Houghton, MI 49931, USA.

Search for more papers by this author

Email the corresponding author at cpeng@mtu.edu

Published Online:24 Jul 2013https://doi.org/10.4155/tde.13.54

View article

Abstract

Drug-delivery carriers have the potential to not only treat but also diagnose many diseases; however, they still lack the complexity of natural-particulate systems. Cell-based therapies using tumor-targeting T cells and tumor-homing mesenchymal stem cells have given researchers a means to exploit the characteristics exhibited by innate-biological entities. Similarly, immune evasion by pathogens has inspired the development of natural polymers to cloak drug carriers. The ‘marker-of-self’ CD47 protein, which is found ubiquitously on mammalian cell surfaces, has been used for evading phagocyte clearance of drug carriers. This review will focus on the recent progress of drug carriers co-opting the tricks that cells in nature use to hide safely under the radar of the body’s innate immune system.

References

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm.50(1),161–177 (2000).Crossref, Medline, CAS, Google Scholar
2 Kalachandra S, Takamata T, Lin D, Snyder E, Webster-Cyriaque J. Stability and release of antiviral drugs from ethylene vinyl acetate (EVA) copolymer. J. Mater. Sci. Mater. Med.17(12),1227–1236 (2006).Crossref, Medline, CAS, Google Scholar
3 Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer6(9),688–701 (2006).Crossref, Medline, CAS, Google Scholar
4 Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev.58(14),1456–1459 (2006).Crossref, Medline, CAS, Google Scholar
5 Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv. Drug Deliv. Rev.65(1),60–70 (2013).Crossref, Medline, CAS, Google Scholar
6 Plummer R, Wilson RH, Calvert H et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer104(4),593–598 (2011).Crossref, Medline, CAS, Google Scholar
7 Blanco E, Hsiao A, Ruiz-Esparza GU et al. Molecular-targeted nanotherapies in cancer: Enabling treatment specificity. Mol. Oncol.5(6),492–503 (2011).Crossref, Medline, CAS, Google Scholar
8 Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov.9(8),615–627 (2010).Crossref, Medline, CAS, Google Scholar
9 Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov.10(7),521–535 (2011).Crossref, Medline, CAS, Google Scholar
10 Verma P, Thakur A, Deshmukh K, Jha A, Verma S. Routes of drug administration. Int. J. Pharm. Studies Res.1(1),54–59 (2010).Google Scholar
11 Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond.)5(2),287–306 (2010).Crossref, Medline, CAS, Google Scholar
12 Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev.56(11),1649–1659 (2012).Crossref, Google Scholar
13 Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release121(1–2),3–9 (2007).Crossref, Medline, CAS, Google Scholar
14 Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR. The shape of things to come: importance of design in nanotechnology for drug delivery. Ther. Deliv.3(2),181–194 (2012).Link, CAS, Google Scholar
15 Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev.16(2–3),195–214 (1995).Crossref, CAS, Google Scholar
16 Abra RM, Bosworth ME, Hunt CA. Liposome disposition in vivo: effects of pre-dosing with lipsomes. Res. Commun. Chem. Pathol. Pharmacol.29(2),349–360 (1980).Medline, CAS, Google Scholar
17 Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discov.2(3),214–221 (2003).Crossref, Medline, CAS, Google Scholar
18 Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today10(21),1451–1458 (2005).Crossref, Medline, CAS, Google Scholar
19 Singh P, Gupta U, Asthana A, Jain NK. Folate and folate–PEG–PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug. Chem.19(11),2239–2252 (2008).Crossref, Medline, CAS, Google Scholar
20 Chow TH, Lin YY, Hwang JJ et al. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Anticancer Res.29(6),2111–2120 (2009).Medline, CAS, Google Scholar
21 Bohl Kullberg E, Bergstrand N, Carlsson J et al. Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug. Chem.13(4),737–743 (2002).Crossref, Medline, Google Scholar
22 Wang J, Peng CA. Anticancer effectiveness of polymeric drug nanocarriers on colorectal cancer cells. Conf. Proc. IEEE Eng. Med. Biol. Soc.52(10),6090883 (2011).Google Scholar
23 Koo AN, Min KH, Lee HJ et al. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links. Biomaterials33(5),1489–1499 (2012).Crossref, Medline, CAS, Google Scholar
24 Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin. Emerg. Drugs14(2),363–380 (2009).Crossref, Medline, CAS, Google Scholar
25 Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev.61(13),1203–1213 (2009).Crossref, Medline, CAS, Google Scholar
26 Yang C, Lu D, Liu Z. How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation. Biochemistry50(13),2585–2593 (2011).Crossref, Medline, CAS, Google Scholar
27 Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev.54(4),531–545 (2002).Crossref, Medline, CAS, Google Scholar
28 Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm.354(1–2),3–8 (2008).Crossref, Medline, CAS, Google Scholar
29 Fisher KD, Seymour LW. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug Deliv. Rev.62(2),240–245 (2010).Crossref, Medline, CAS, Google Scholar
30 Pike DB, Ghandehari H. HPMA copolymer–cyclic RGD conjugates for tumor targeting. Adv. Drug Deliv. Rev.62(2),167–183 (2010).Crossref, Medline, CAS, Google Scholar
31 Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem. Int. Ed. Engl.49(36),6288–6308 (2010).▪ Advantages and disadvantages of PEGylation are thoroughly discussed.Crossref, Medline, CAS, Google Scholar
32 Lammers T, Ulbrich K. HPMA copolymers: 30 years of advances. Adv. Drug Deliv. Rev.62(2),119–121 (2010).Crossref, Medline, CAS, Google Scholar
33 Kopeček J, Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev.62(2),122–149 (2010).Crossref, Medline, CAS, Google Scholar
34 Evans EA. Structure and deformation properties of red blood cells: concepts and quantitative methods. Methods Enzymol.173,3–35 (1989).Crossref, Medline, CAS, Google Scholar
35 Finlay BB, McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell124(4),767–782 (2006).Crossref, Medline, CAS, Google Scholar
36 Swann JB, Smyth MJ. Immune surveillance of tumors. J. Clin. Invest.117(5),1137–1146 (2007).Crossref, Medline, CAS, Google Scholar
37 Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol.11(9),785–797 (2010).Crossref, Medline, CAS, Google Scholar
38 Klein G. Immune and non-immune surveillance in cancer. Atlas Genet. Cytogenet. Oncol. Haematol.17,114–147 (2013).Google Scholar
39 Chen K, Xu W, Wilson M et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat. Immunol.10(8),889–898 (2009).Crossref, Medline, CAS, Google Scholar
40 Chin AI, Miyahira AK, Covarrubias A et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res.70(7),2595–2603 (2010).Crossref, Medline, CAS, Google Scholar
41 Ihler GM, Glew RH, Schnure FW. Enzyme loading of erythrocytes. Proc. Natl Acad. Sci. USA70(9),2663–2666 (1973).Crossref, Medline, CAS, Google Scholar
42 Sprandel U, Hubbard AR, Chalmers RA. In vitro studies on resealed erythrocyte ghosts as protein carriers. Res. Exp. Med.175(3),239–245 (1979).Crossref, Medline, CAS, Google Scholar
43 Oldenborg PA, Zheleznyak A, Fang YF et al. Role of CD47 as a marker of self on red blood cells. Science288(5473),2051–2054 (2000).▪ First artcle showing that CD47 functioned as a marker-of-self on red blood cells as well as a discussion of the CD47–SIRPα interaction.Crossref, Medline, CAS, Google Scholar
44 Khandelwal S, Van Rooijen N, Saxena Rajiv K. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion47(9),1725–1732 (2007).Crossref, Medline, Google Scholar
45 Soto-Pantoja DR, Stein EV, Rogers NM et al. Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin. Ther. Targets17(1),89–103 (2013).Crossref, Medline, CAS, Google Scholar
46 Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol.11(3),130–135 (2001).Crossref, Medline, CAS, Google Scholar
47 Oldenborg PA. CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease. ISRN Hematol.2013,614619 (2013).Crossref, Medline, Google Scholar
48 Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells21(1),105–110 (2003).Crossref, Medline, Google Scholar
49 Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Deliv. Rev.64(8),739–748 (2012).▪ In-depth review of current mesenchymal stem cell-based cancer therapies and their clinical impact.Crossref, Medline, CAS, Google Scholar
50 Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature418(6893),41–49 (2002).Crossref, Medline, CAS, Google Scholar
51 Corsten MF, Shah K. Therapeutic stem cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol.9(4),376–384 (2008).Crossref, Medline, Google Scholar
52 Momin EN, Vela G, Zaidi HA, Quinones-Hinojosa A. The oncogenic potential of mesenchymal stem cells in the treatment of cancer: directions for future research. Curr. Immunol. Rev.6(2),137–148 (2010).Crossref, Medline, CAS, Google Scholar
53 Cihova M, Altanerova V, Altaner C. Stem cell based cancer gene therapy. Mol. Pharm.8(5),1480–1487 (2011).Crossref, Medline, CAS, Google Scholar
54 Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature319(6055),675–678 (1986).Crossref, Medline, CAS, Google Scholar
55 Batista FD, Dustin ML. Cell:cell interactions in the immune system. Immunol. Rev.251(1),7–12 (2013).Crossref, Medline, CAS, Google Scholar
56 Chao MP, Alizadeh AA, Tang C et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell142(5),699–713 (2010).Crossref, Medline, CAS, Google Scholar
57 Willingham SB, Volkmer JP, Gentles AJ et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA109(17),6662–6667 (2012).▪ CD47 expression on tumor cells is used as a target for cancer therapies.Crossref, Medline, CAS, Google Scholar
58 Zhao XW, van Beek EM, Schornagel K et al. CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl Acad. Sci. USA108(45),18342–18347 (2011).Crossref, Medline, CAS, Google Scholar
59 Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol.31(6),212–219 (2010).Crossref, Medline, CAS, Google Scholar
60 Rosenberger CM, Finlay BB. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nat. Rev. Mol. Cell Biol.4(5),385–396 (2003).Crossref, Medline, CAS, Google Scholar
61 Shao F, Merritt PM, Bao Z, Innes RW, Dixon JE. A Yersinia effector and a Pseudomonas avirulence protein define a family of cysteine proteases functioning in bacterial pathogenesis. Cell109(5),575–588 (2002).Crossref, Medline, CAS, Google Scholar
62 Biedzka-Sarek M, Jarva H, Hyytiäinen H, Meri S, Skurnik M. Characterization of complement factor H binding to Yersinia enterocolitica serotype O:3. Infect. Immun.76(9),4100–4109 (2008).Crossref, Medline, CAS, Google Scholar
63 Rooijakkers SH, van Strijp JA. Bacterial complement evasion. Mol. Immunol.44(1–3),23–32 (2007).Crossref, Medline, CAS, Google Scholar
64 Pier GB. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int. J. Med. Microbiol.297(5),277–295 (2007).Crossref, Medline, CAS, Google Scholar
65 Dale JB, Washburn RG, Marques MB, Wessels MR. Hyaluronate capsule and surface M protein in resistance to opsonization of group A Streptococci.Infect. Immun.64(5),1495–1501 (1996).Crossref, Medline, CAS, Google Scholar
66 Moses AE, Wessels MR, Zalcman K et al. Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect. Immun.65(1),64–71 (1997).Crossref, Medline, CAS, Google Scholar
67 Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat. Med.4(6),679–684 (1998).Crossref, Medline, CAS, Google Scholar
68 Hu CMJ, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv. Healthc. Mater.1(5),537–547 (2012).Crossref, Medline, CAS, Google Scholar
69 Bax BE, Bain MD, Talbot PJ, Parker-Williams EJ, Chalmers RA. Survival of human carrier erythrocytes in vivo.Clin. Sci.96(2),171–178 (1999).Crossref, Medline, CAS, Google Scholar
70 Godfrin Y, Horand F, Franco R et al. International seminar on the red blood cells as vehicles for drugs. Expert Opin. Biol. Ther.12(1),127–133 (2012).Crossref, Medline, Google Scholar
71 Magnani M. Erythrocytes as carriers for drugs: the transition from the laboratory to the clinic is approaching. Expert Opin. Biol. Ther.12(2),137–138 (2012).Crossref, Medline, CAS, Google Scholar
72 Domenech C, Thomas X, Chabaud S et al. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005–2001 randomized trial. Br. J. Haematol.153(1),58–65 (2011).Crossref, Medline, CAS, Google Scholar
73 Moran NF, Bain MD, Muqit MM, Bax BE. Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology71(9),686–688 (2008).Crossref, Medline, CAS, Google Scholar
74 Kim SH, Kim EJ, Hou JH et al. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides. Biomaterials30(5),959–967 (2009).Crossref, Medline, Google Scholar
75 Byun HM, Suh D, Yoon H et al. Erythrocyte ghost-mediated gene delivery for prolonged and blood-targeted expression. Gene Ther.11(5),492–496 (2004).Crossref, Medline, CAS, Google Scholar
76 Kwon YM, Chung HS, Moon C et al. l-asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J. Control. Release139(3),182–189 (2009).Crossref, Medline, CAS, Google Scholar
77 Delcea M, Sternberg N, Yashchenok AM et al. Nanoplasmonics for dual-molecule release through nanopores in the membrane of red blood cells. ACS Nano6(5),4169–4180 (2012).Crossref, Medline, CAS, Google Scholar
78 Cinti C, Taranta M, Naldi I, Grimaldi S. Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds. PLoS ONE6(2),0017132 (2011).Crossref, Google Scholar
79 Lejeune A, Poyet P, Gaudreault RC, Gicquaud C. Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action? Anticancer Res.17(5A),3599–3603 (1997).Medline, CAS, Google Scholar
80 Hu CMJ, Zhang L, Aryal S et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA108(27),10980–10985 (2011).▪▪ First paper showing that nanoparticles can be coated with erythrocyte membranes while still keeping the membrane proteins and lipids intact.Crossref, Medline, CAS, Google Scholar
81 Zaitsev S, Danielyan K, Murciano JC et al. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood108(6),1895–1902 (2006).Crossref, Medline, CAS, Google Scholar
82 Chambers E, Mitragotri S. Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp. Biol. Med.232(7),958–966 (2007).CAS, Google Scholar
83 Doshi N, Zahr AS, Bhaskar S, Lahann J, Mitragotri S. Red blood cell-mimicking synthetic biomaterial particles. Proc. Natl Acad. Sci. USA106(51),21495–21499 (2009).Crossref, Medline, CAS, Google Scholar
84 Merkel TJ, Jones SW, Herlihy KP et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl Acad. Sci. USA108(2),586–591 (2011).Crossref, Medline, CAS, Google Scholar
85 Marin V, Dander E, Biagi E et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp. Hematol.34(9),1218–1228 (2006).Crossref, Google Scholar
86 Chan JK, Hamilton CA, Cheung MK et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin. Cancer Res.12(6),1859–1867 (2006).Crossref, Medline, CAS, Google Scholar
87 Mesiano G, Todorovic M, Gammaitoni L et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin. Biol. Ther.12(6),673–684 (2012).Crossref, Medline, CAS, Google Scholar
88 Koh MBC, Ching Linn Y. Clinical expansion of cytokine induced killer (CIK) cells. ISBT Sci. Ser.7(1),154–156 (2012).Crossref, CAS, Google Scholar
89 Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant.11(3),181–187 (2005).Crossref, Medline, Google Scholar
90 Linn YC, Yong HX, Niam M et al. A Phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy14(7),851–859 (2012).Crossref, Medline, CAS, Google Scholar
91 Verneris MR, Baker J, Edinger M, Negrin RS. Studies of ex vivo activated and expanded CD8⁺ NK-T cells in humans and mice. J. Clin. Immunol.22(3),131–136 (2002).Crossref, Medline, CAS, Google Scholar
92 Kerkar SP, Muranski P, Kaiser A et al. Tumor-specific CD8⁺ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hoststs. Cancer Res.70(17),6725–6734 (2010).Crossref, Medline, CAS, Google Scholar
93 Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol.31(1),71–75 (2013).Crossref, Medline, CAS, Google Scholar
94 Qiao L, Xu Z, Zhao T et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res.18(4),500–507 (2008).Crossref, Medline, CAS, Google Scholar
95 Menon LG, Picinich S, Koneru R et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells25(2),520–528 (2007).Crossref, Medline, CAS, Google Scholar
96 Chen X, Lin X, Zhao J et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther.16(4),749–756 (2008).Crossref, Medline, CAS, Google Scholar
97 Okada H, Pollack IF. Cytokine gene therapy for malignant glioma. Expert Opin. Biol. Ther.4(10),1609–1620 (2004).Crossref, Medline, CAS, Google Scholar
98 Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther.11(14),1155–1164 (2004).Crossref, Medline, CAS, Google Scholar
99 Gunnarsson S, Bexell D, Svensson A et al. Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNγ-transduced tumor cell immunotherapy of experimental glioma. J. Neuroimmunol.218(1–2),140–144 (2010).Crossref, Medline, CAS, Google Scholar
100 Danks MK, Yoon KJ, Bush RA et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res.67(1),22–25 (2007).Crossref, Medline, CAS, Google Scholar
101 Aboody KS, Brown A, Rainov NG et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA97(23),12846–12851 (2000).Crossref, Medline, CAS, Google Scholar
102 Kosaka H, Ichikawa T, Kurozumi K et al. Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. Cancer Gene Ther.19(8),572–578 (2012).Crossref, Medline, CAS, Google Scholar
103 Fei S, Qi X, Kedong S et al. The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. J. Cancer Res. Clin. Oncol.138(2),347–357 (2012).Crossref, Medline, Google Scholar
104 Mori K, Iwata J, Miyazaki M et al. Bystander killing effect of thymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells. Neurol. Med. Chir.50(7),545–553 (2010).Crossref, Medline, Google Scholar
105 Nakashima H, Kaur B, Chiocca EA. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev.21(2–3),119–126 (2010).Crossref, Medline, CAS, Google Scholar
106 Willmon C, Harrington K, Kottke T et al. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther.17(10),1667–1676 (2009).Crossref, Medline, CAS, Google Scholar
107 Ilett EJ, Prestwich RJ, Kottke T et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther.16(5),689–699 (2009).Crossref, Medline, CAS, Google Scholar
108 Garcia-Castro J, Alemany R, Cascallo M et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther.17(7),476–483 (2010).Crossref, Medline, CAS, Google Scholar
109 Yong RL, Shinojima N, Fueyo J et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res.69(23),8932–8940 (2009).Crossref, Medline, CAS, Google Scholar
110 Pain D, Das PK, Ghosh P, Bachhawat BK. Increased circulatory half-life of liposomes after conjunction with dextran. J. Biosci.6(6),811–816 (1984).Crossref, CAS, Google Scholar
111 Sarwat F, Ul Qader SA, Aman A, Ahmed N. Production and characterization of a unique dextran from an indigenous Leuconostoc mesenteroides CMG713. Int. J. Biol. Sci.4(6),379–386 (2008).Crossref, Medline, CAS, Google Scholar
112 McCahon R, Hardman J. Pharmacology of plasma expanders. Anaesth. Intensive Care11(2),75–77 (2010).Crossref, Google Scholar
113 Tu J, Zhong S, Li P. Studies on acyclovir–dextran conjugate: synthesis and pharmacokinetics. Drug Dev. Ind. Pharm.30(9),959–965 (2004).Crossref, Medline, CAS, Google Scholar
114 Houga CM, Giermanska J, Lecommandoux SB et al. Micelles and polymersomes obtained by self-assembly of dextran and polystyrene based block copolymers. Biomacromolecules10(1),32–40 (2008).Crossref, Google Scholar
115 Ma WJ, Yuan XB, Kang CS et al. Evaluation of blood circulation of polysaccharide surface-decorated PLA nanoparticles. Carbohydr. Polym.72(1),75–81 (2008).Crossref, CAS, Google Scholar
116 Passirani C, Barratt G, Devissaguet JP, Labarre D. Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res.15(7),1046–1050 (1998).Crossref, Medline, CAS, Google Scholar
117 Chao Y, Makale M, Karmali PP et al. Recognition of dextran–superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. Bioconjug. Chem.23(5),1003–1009 (2012).Crossref, Medline, CAS, Google Scholar
118 Gonçalves C, Martins JA, Gama FM. Self-assembled nanoparticles of dextrin substituted with hexadecanethiol. Biomacromolecules8(2),392–398 (2007).Crossref, Medline, CAS, Google Scholar
119 Gonçalves C, Torrado E, Martins T et al. Dextrin nanoparticles: studies on the interaction with murine macrophages and blood clearance. Colloids Surf. B75(2),483–489 (2010).Crossref, Medline, CAS, Google Scholar
120 Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer108(5),780–789 (2004).Crossref, Medline, CAS, Google Scholar
121 Mizrahy S, Raz SR, Hasgaard M et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J. Control. Release156(2),231–238 (2011).Crossref, Medline, CAS, Google Scholar
122 Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol. Today21(9),447–455 (2000).Crossref, Medline, CAS, Google Scholar
123 Rema RB, Rajendran K, Ragunathan M. Angiogenic efficacy of Heparin on chick chorioallantoic membrane. Vasc. Cell4(1),4–8 (2012).Crossref, Medline, Google Scholar
124 Berry D, Shriver Z, Natke B et al. Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1. Biochem. J.373,241–249 (2003).Crossref, Medline, CAS, Google Scholar
125 Wang Z, Ly M, Zhang F et al.E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol. Bioeng.107(6),964–973 (2010).Crossref, Medline, CAS, Google Scholar
126 Kemp MM, Linhardt RJ. Heparin-based nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.2(1),77–87 (2010).Crossref, Medline, CAS, Google Scholar
127 Nguyen TH, Kim SH, Decker CG et al. A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nat. Chem.5(3),221–227 (2013).Crossref, Medline, CAS, Google Scholar
128 Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev.53(2),283–318 (2001).▪▪ Strategies for fabricating drug carriers with long-circulating and site-targeting features are discussed. The ability of microorganisms to evade macrophage recognition is also explored.Medline, CAS, Google Scholar
129 Hsu YC, Acuña M, Tahara S, Peng CA. Reduced phagocytosis of colloidal carriers using soluble CD47. Pharm. Res.20(10),1539–1542 (2003).▪ First article to use soluble CD47 to demonstrate antiphagocytic effect to microparticles.Crossref, Medline, CAS, Google Scholar
130 Tsai RK, Discher DE. Inhibition of ‘self’ engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol.180(5),989–1003 (2008).Crossref, Medline, CAS, Google Scholar
131 Rodriguez PL, Harada T, Christian DA et al. Minimal ‘self’ peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science339(6122),971–975 (2013).▪▪ ‘Self’ peptide from CD47 was synthesized and demonstrated antiphagocytic effect to nanoparticles.Crossref, Medline, CAS, Google Scholar
132 Ishihara T, Takeda M, Sakamoto H et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res.26(10),2270–2279 (2009).Crossref, Medline, CAS, Google Scholar
133 Sroda K, Rydlewski J, Langner M et al. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell. Mol. Biol. Lett.10(1),37–47 (2005).Medline, CAS, Google Scholar
134 Armstrong JK, Hempel G, Koling S et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer110(1),103–111 (2007).Crossref, Medline, Google Scholar
135 Schellenberger V, Wang CW, Geething NC et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol.27(12),1186–1190 (2009).Crossref, Medline, CAS, Google Scholar
136 Geething NC, To W, Spink BJ et al. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS ONE5(4),0010175 (2010).Crossref, Google Scholar
137 Garratty G. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang.94(2),87–95 (2008).Medline, CAS, Google Scholar
138 Barry MA, Campos SK, Ghosh D et al. Biotinylated gene therapy vectors. Expert Opin. Biol. Ther.3(6),925–940 (2003).Crossref, Medline, CAS, Google Scholar
139 Murphy EA, Majeti BK, Barnes LA et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA105(27),9343–9348 (2008).Crossref, Medline, CAS, Google Scholar
201 XL-protein. www.xl-protein.comGoogle Scholar
202 Amunix. www.amunix.comGoogle Scholar

Vol. 4, No. 7

Metrics

Downloaded 132 times

History

Published online 24 July 2013

Published in print July 2013

Information

Financial & competing interest disclosure

The preparation of this article and the work of the authors mentioned therein were supported financially by the NIH (R15 CA152828-01). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download